Haemonetics accounting chief sells 836 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Haemonetics Corp. (HAE) VP, Chief Accounting Officer Farris Maryanne Maunsell exercised options for 1,068 shares at $89.16, 645 shares at $95.73, and 433 shares at $70.31 on November 11, 2026, acquiring the corresponding common shares. She also delivered or had withheld 1,724 shares for payment of exercise price or tax liability, and sold 836 shares at a weighted average price of $120.99 in multiple transactions ranging from $120.87 to $121.10. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified Stock Option (Right to Buy) F4 | 1,068 | $0.00 | $0.00 |
| Exercise | Non-qualified Stock Option (Right to Buy) F4 | 645 | $0.00 | $0.00 |
| Exercise | Non-qualified Stock Option (Right to Buy) F4 | 433 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,068 | $89.16 | $95K |
| Exercise | Common Stock F1 | 645 | $95.73 | $62K |
| Exercise | Common Stock F1 | 433 | $70.31 | $30K |
| Exercise Price or Tax Liability | Common Stock F2, F1 | 1,724 | $121.10 | $209K |
| Sale | Common Stock F3, F1 | 836 | $120.99 | $101K |
Footnotes (4)
- F1. This number includes unvested restricted stock units ("RSUs") previously reported.
- F2. Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- F4. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Key Figures
Key Terms
Non-qualified Stock Option (Right to Buy) technical
weighted average price financial
restricted stock units financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How do Farris Maryanne Maunsell’s Haemonetics options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.